Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) Senior Officer Kirk Look purchased 12,800 shares of the company's stock in a transaction that occurred on Tuesday, July 15th. The stock was bought at an average cost of C$1.60 per share, for a total transaction of C$20,517.12.
Oncolytics Biotech Price Performance
Shares of TSE:ONC traded down C$0.05 during trading on Friday, reaching C$1.73. The stock had a trading volume of 245,934 shares, compared to its average volume of 147,357. The business has a fifty day moving average price of C$0.90 and a 200-day moving average price of C$0.95. Oncolytics Biotech Inc. has a 1-year low of C$0.44 and a 1-year high of C$2.08. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The stock has a market cap of C$133.34 million, a PE ratio of -4.82 and a beta of 1.35.
Analyst Upgrades and Downgrades
Separately, Jones Trading lowered shares of Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th.
Read Our Latest Stock Report on ONC
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Further Reading
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
